Abstract
Cancer disease is characterized by genomic abnormalities and gene expression aberrations that leads to misregulated activity of apoptosis, angiogenesis and cell proliferation. Heterogeneous ribonucleoprotein K (hnRNP K) is a constitutive protein found in nucleus, cytoplasm and mitochondria of cells and interacts with molecules involved in gene expression and signal transduction pathways. It is believed that the over expression of hnRNP K leads to prostate, breast and colorectal cancer types. The binding to nucleotides is the main interaction that triggers biological activity and is mediated by its three K homology (KH) domains. Trying to optimize a phenylbenzamide derivative, already reported as an hnRNP K ligand, and design novel ligand candidates with anticancer activity, synthetically viable phenylbenzamide derivatives coupled to pyrimidine nucleosides were evaluated in silico by docking simulations with KH3 domain of hnRNP K. The cytosine nucleoside and phenylbenzamide moieties could be able of simulating the polar interactions performed by natural celular nucleotide ligands with ARG40 and ARG59, the main residues of KH3 domain responsible for nucleotide recognition. Ligand-based in silico biological activity spectrum evaluation also revealed that phenylbenzamide coupled to pyrimidine nucleosides are potential anticancer candidates.
Keywords: Biological activity spectrum, cancer, hnRNP K, phenylbenzamide derivatives, pyrimidines.
Graphical Abstract
Current Bioactive Compounds
Title:In Silico Design of Phenylbenzamide Derivatives Coupled to Pyrimidines as Novel hnRNP K Ligands Against Cancer
Volume: 10 Issue: 3
Author(s): Matheus G. de Oliveira, Andreza S. Figueredo, Gilberto L.B. de Aquino, Andreia M. Leopoldino, Vinicius B. da Silva, Carlton A. Taft and Carlos H.T. de Paula da Silva
Affiliation:
Keywords: Biological activity spectrum, cancer, hnRNP K, phenylbenzamide derivatives, pyrimidines.
Abstract: Cancer disease is characterized by genomic abnormalities and gene expression aberrations that leads to misregulated activity of apoptosis, angiogenesis and cell proliferation. Heterogeneous ribonucleoprotein K (hnRNP K) is a constitutive protein found in nucleus, cytoplasm and mitochondria of cells and interacts with molecules involved in gene expression and signal transduction pathways. It is believed that the over expression of hnRNP K leads to prostate, breast and colorectal cancer types. The binding to nucleotides is the main interaction that triggers biological activity and is mediated by its three K homology (KH) domains. Trying to optimize a phenylbenzamide derivative, already reported as an hnRNP K ligand, and design novel ligand candidates with anticancer activity, synthetically viable phenylbenzamide derivatives coupled to pyrimidine nucleosides were evaluated in silico by docking simulations with KH3 domain of hnRNP K. The cytosine nucleoside and phenylbenzamide moieties could be able of simulating the polar interactions performed by natural celular nucleotide ligands with ARG40 and ARG59, the main residues of KH3 domain responsible for nucleotide recognition. Ligand-based in silico biological activity spectrum evaluation also revealed that phenylbenzamide coupled to pyrimidine nucleosides are potential anticancer candidates.
Export Options
About this article
Cite this article as:
Oliveira G. de Matheus, Figueredo S. Andreza, Aquino L.B. de Gilberto, Leopoldino M. Andreia, Silva B. da Vinicius, Taft A. Carlton and Silva H.T. de Paula da Carlos, In Silico Design of Phenylbenzamide Derivatives Coupled to Pyrimidines as Novel hnRNP K Ligands Against Cancer, Current Bioactive Compounds 2014; 10 (3) . https://dx.doi.org/10.2174/157340721003141013142614
DOI https://dx.doi.org/10.2174/157340721003141013142614 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Molecular Docking Analysis of Flavonoid Compounds with Matrix Metalloproteinase- 8 for the Identification of Potential Effective Inhibitors
Letters in Drug Design & Discovery Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway
Anti-Cancer Agents in Medicinal Chemistry An Emerging Therapeutic Approach by Targeting Myoferlin (MYOF) for Malignant Tumors
Current Topics in Medicinal Chemistry Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Genomic Instability and Carcinogenesis: An Update
Current Genomics Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems
Current Drug Discovery Technologies Synthesis of Metronidazole Derivatives Containing Pyridine Ring and Anticancer Activity
Letters in Organic Chemistry Drug Transporters in Chemotherapy Induced Peripheral Neurotoxicity:Current Knowledge and Clinical Implications
Current Medicinal Chemistry Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
Current Medicinal Chemistry Prospects of Utilizing Computational Techniques for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Bioconjugation of Polymers: A Novel Platform for Targeted Drug Delivery
Current Pharmaceutical Design Corneal Neovascularization: Molecular Events and Therapeutic Options
Recent Patents on Inflammation & Allergy Drug Discovery Organic Antifungal Drugs and Targets of Their Action
Current Topics in Medicinal Chemistry CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets